Summary of Key Achievements in Leukemia Treatment Over the Past Eight Years
Over the past eight years, there have been revolutionary breakthroughs in leukemia treatment, transforming this once incurable disease into one that can be managed and controlled, with some patients achieving long-term survival or even a cure. Key advancements include:
- For chronic myeloid leukemia (CML), the use of targeted therapies and increased healthcare coverage have reduced the cost of life-saving medications, shifting the focus from expensive treatments to long-term management of the chronic condition.
- The "Shanghai Protocol" developed by Chinese doctors has led to a cure rate of over 90% for the most aggressive form of acute promyeloid leukemia (APL).
- The "Beijing Protocol" has solved the problem of matching donors for hematopoietic stem cell transplants, which was previously a major challenge.
- Immunotherapies such as CAR-T have provided new hope for patients with relapsed or refractory diseases, and cutting-edge technologies like mRNA vaccines are also being rapidly explored.
1. Chronic Myeloid Leukemia: From Unaffordable Treatment to Chronic Disease Management
The drug Gleevec (imatinib), featured in the film "Dying to Survive," is a game-changer for CML by targeting the faulty genetic switch (BCR::ABL1 fusion gene) within cancer cells. Initially, imported Gleevec was prohibitively expensive, out of reach for many families. However, with the introduction of domestically produced generic versions and centralized purchasing initiatives, the cost has been reduced to around 624 yuan per box. Coupled with healthcare reimbursement, the monthly out-of-pocket cost is only about 1,000 yuan. Today, CML patients can lead normal lives with regular medication and regular check-ups, much like patients with hypertension. In case of drug resistance, third-generation domestic drugs (such as olaribatinib) are available as a backup. CML has evolved from a life-threatening cancer to a chronic condition that requires long-term medication.
2. The Shanghai Protocol: Turning the Most Aggressive Form of Leukemia into a Highly Curable Disease
Acute promyeloid leukemia (APL) was once one of the most severe types of leukemia, with patients prone to severe bleeding and potential death within a short period. Chinese doctors have made significant progress by combining two innovative treatments:
- In the 1970s, Professor Zhang Tingdong discovered that arsenic derivatives could kill APL cells.
- In the 1980s, the team led by Academician Wang Zhenyi identified all-trans retinoic acid, which could induce abnormal leukemia cells to differentiate and mature normally.
- Later, the teams of Chen Zhu and Chen Saijuan combined these treatments to develop the "Shanghai Protocol," which not only induces cell differentiation but also directly kills the malignant cells. As a result, the 5-year survival rate for APL patients now exceeds 90%, making it one of the most curable types of leukemia in adults.
3. The Beijing Protocol: Ensuring Donor Matches for Every Patient
Hematopoietic stem cell transplants are a potential cure for certain high-risk leukemias, but the requirement for a perfect HLA match between donor and recipient made finding a donor extremely difficult, with the chance of a match between siblings being only 1 in 4. After 20 years of research, the team led by Professor Huang Xiaojun from Peking University developed the "semi-matched transplant" approach, which allows relatives (such as parents and children) to serve as donors. With pre-treatment of the donor's stem cells and the use of immunosuppressive drugs, the semi-matched cells can successfully implant in the patient's body without causing rejection. This approach, known internationally as the "Beijing Protocol," has significantly increased the availability of donor matches.
4. CAR-T Therapy: Arming Patients' Immune System to Target Cancer Cells
While targeted therapies and transplants address different aspects of cancer treatment, CAR-T therapy takes a different approach. It involves extracting T cells from the patient's blood, modifying them in the laboratory to recognize specific markers on cancer cells, and then reinfusing them into the patient's body. These modified T cells can efficiently target and destroy cancer cells. Domestic CAR-T therapies, such as Naxolentis from Hengyuan Bio and Pukielunsai from Chongqing Precision Bio (the first CAR-T therapy for childhood leukemia in China), have been approved for use. However, CAR-T therapy also has challenges, including high costs and potential side effects like fever and low blood pressure.
5. The Future: mRNA Vaccines and Other Technologies for More Personalized Cancer Treatment
Along with CAR-T, mRNA vaccines represent another promising direction in cancer research. These vaccines use mRNA to teach the immune system to recognize unique cancer antigens, allowing for more precise attacks on cancer cells. Although still in clinical trials (mainly for solid tumors), domestic companies are already making progress:
- Yunding Newgen's EVM16 has induced an immune response against new antigens in 80% of trial participants.
- Likang Life's LK101 is the first personalized tumor vaccine in China, currently undergoing trials for lung cancer.
These technologies, along with CAR-T, are transforming cancer treatment from a search for a single effective drug to a tailored approach for each patient. The progress in leukemia treatment is a testament to the innovative contributions of Chinese doctors, as well as the impact of reduced drug costs and expanded healthcare coverage. With the introduction of more new technologies, the quality of life for leukemia patients is expected to continue to improve.